Pharmaceuticals, Biotechnology and Life Sciences
Viralym-M pivotal and proof-of-concept studies to be initiated in 2020 for treatment and prevention of severe and life-threatening viral diseases…
Study to Evaluate the Pressure-Enabled Drug Delivery™ Approach Combined with Standard of Care Chemotherapy to Enable Deep Tumor Penetration and…
– Completed Last Patient Last Visit for STRIDE 3 Dry Eye Disease Trial; Topline Results on Track for First Quarter…
TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter…
NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and…
In Pivotal Phase 3 KEYNOTE-355 Study, KEYTRUDA Plus Chemotherapy Significantly Improved PFS Compared to Chemotherapy Alone in Patients with mTNBC…
DUBLIN–(BUSINESS WIRE)–The “Partnerships, Licensing, Investments and M&A Deals and Trends for November 2019 in Pharmaceuticals” report has been added to…
TORONTO–(BUSINESS WIRE)–Cybin, Canada’s premier medicinal mushroom life sciences company with a core focus on advancing psilocybin research and intellectual property…
DOVER, Del.–(BUSINESS WIRE)–#RWD—Inteliquet, a leading provider of intelligent technology, advanced insights, and expertise for clinical research, patient treatment and translational…
Linagliptin did not increase the risk of adverse cardiovascular events, hospitalization for heart failure or adverse kidney events compared with…